Latest Headlines

  1. DP Technology And Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods To Accelerate ADC Drug Innovation 11/21/2024

    Lepu Biopharma Co., Ltd. (Lepu Biopharma) and Beijing DP Tech Co., Ltd. (DP Technology) have recently announced a significant milestone in their Antibody-Drug Conjugate (ADC) drug collaboration.

  2. Laekna Announces A Clinical Collaboration With Lilly To Develop LAE102, A Novel Monoclonal Antibody Targeting Activin Receptor Type 2A For The Treatment Of Obesity 11/20/2024

    Laekna, Inc. a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a clinical collaboration with Eli Lilly and Company (Lilly), a global leader in cardiometabolic health, including diabetes and obesity, to accelerate the development of LAE102, a novel ActRIIA mAb as a novel treatment for obesity.

  3. Queen Mary University Of London Seeks To Advance AI For Drug Discovery 11/20/2024

    Queen Mary University of London has agreed a new collaborative research project with AstraZeneca to advance AI for drug discovery.

  4. Recursion And Exscientia, Two Leaders In The AI Drug Discovery Space, Have Officially Combined To Advance The Industrialization Of Drug Discovery 11/20/2024

    The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq: EXAI) ceased trading and will be delisted from Nasdaq.

  5. GeneDx Fuels Rare Disease Drug Discovery With Launch Of GeneDx Discover 11/19/2024

    GeneDx a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx’s robust database - to improve all stages of drug development.

  6. Sangamo Therapeutics Announces U.S. FDA Clearance Of IND Application For ST-503 For The Treatment Of Idiopathic Small Fiber Neuropathy, A Type Of Chronic Neuropathic Pain 11/19/2024

    Sangamo Therapeutics, Inc. a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for its ST-503 program, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain.

  7. RiDYMO® Platform Drives New Breakthroughs In Highly Potent PLK1 Inhibitors Development 11/19/2024

    With the support of the RiDYMO® platform, we are able to comprehensively explore various potential targets in drug development, including protein-protein interactions, kinases, GPCRs, ion channels, and transcription factors.

  8. Arrowhead Pharmaceuticals Submits New Drug Application To U.S. FDA For Plozasiran For The Treatment Of Familial Chylomicronemia Syndrome 11/18/2024

    Arrowhead Pharmaceuticals, Inc. today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no FDA approved treatments.

  9. Contineum Therapeutics Expands Clinical Development Of PIPE-791 With FDA Authorization Of Its Investigational New Drug (IND) Application For Chronic Pain 11/18/2024

    Contineum Therapeutics, Inc. (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced authorization of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for PIPE-791 for the treatment of chronic pain associated with two separate indications, osteoarthritis (OA) and low back pain (LBP). PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R).

  10. VelaVigo Announces Exclusive Option Agreement With Avenzo To License A Potential First-In-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate 11/18/2024

    VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), today announced it has entered into an agreement with Avenzo Therapeutics, Inc. (Avenzo) granting Avenzo an exclusive option to an exclusive license to develop, manufacture and commercialize a potential first-in-class Nectin4/TROP2 bispecific ADC globally (excluding Greater China).